Recent failures of AI hallucination control at large firms give weight to concerns that AI systems have deeply problematic aspects when it comes to auditing.
This year’s Best Firms for Women prioritize trust and flexibility, curating a friendly work environment, and remembering that their employees are, first and foremost, human beings
Intuit, seeking to repair its somewhat tense relationship with the accounting community, has hired Dixie McCurley, previously of firm Cherry Bekaert, as its very first “managing partner in residence.”
BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.
Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week showing its clinically meaningful benefit in older patients who are able to walk.
Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cytokine release.